Last reviewed · How we verify
NI-1801 in combination with paclitaxel
NI-1801 in combination with paclitaxel is a Small molecule drug developed by Light Chain Bioscience - Novimmune SA. It is currently in Phase 1 development.
At a glance
| Generic name | NI-1801 in combination with paclitaxel |
|---|---|
| Sponsor | Light Chain Bioscience - Novimmune SA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NI-1801 in combination with paclitaxel CI brief — competitive landscape report
- NI-1801 in combination with paclitaxel updates RSS · CI watch RSS
- Light Chain Bioscience - Novimmune SA portfolio CI
Frequently asked questions about NI-1801 in combination with paclitaxel
What is NI-1801 in combination with paclitaxel?
NI-1801 in combination with paclitaxel is a Small molecule drug developed by Light Chain Bioscience - Novimmune SA.
Who makes NI-1801 in combination with paclitaxel?
NI-1801 in combination with paclitaxel is developed by Light Chain Bioscience - Novimmune SA (see full Light Chain Bioscience - Novimmune SA pipeline at /company/light-chain-bioscience-novimmune-sa).
What development phase is NI-1801 in combination with paclitaxel in?
NI-1801 in combination with paclitaxel is in Phase 1.